Skip to main content

Table 1 Baseline characteristics of the study groups: Japanese data

From: Interleukin-6: a new therapeutic target

  

Tocilizumab

Characteristic

Placebo

4 mg/kg

8 mg/kg

n

53

54

55

Age (years)

53

54

56

Sex (male/female)

14/39

14/40

9/46

RA duration (years)

8.4

7.3

8.3

Previous DMARD use

5

4

5

Tender joint count

18 ± 8

19 ± 9

18 ± 10

Swollen joint count

14 ± 6

16 ± 9

14 ± 7

ESR (mm/hour)

69 ± 31

71 ± 29

67 ± 31

CRP (mg/dl)

5.5 ± 4.2

4.7 ± 2.9

4.5 ± 3.3

  1. CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis. Adapted, with permission, from [12].